Inovio Pharmaceuticals (INO) says preclinical testing of a MERS vaccine "induced robust and durable immune responses."
More specifically, "vaccine constructs were observed to induce strong neutralizing antibodies and broad CD8+ T cells in mice."
Although less contagious, the fatality rate for MERS is around five times that for SARS. (PR)
INO +16% premarket
Subscribe for full text news in your inbox